2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Ulf Landmesser, Philippe Charron et al.|European Heart Journal|2023Cited by 2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Artur Oręziak et al.|The Lancet|2020Cited by 1.2k
Genotype and Lifetime Burden of Disease in Hypertrophic CardiomyopathyCarolyn Y. Ho, Sharlene M. Day, Michelle Michels et al.|Circulation|2018Cited by 837
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyChristopher N. Toepfer, Christine E. Seidman, Amanda C. Garfinkel et al.|Circulation|2020Cited by 327
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277